{"id":22312,"date":"2023-02-03T18:35:00","date_gmt":"2023-02-03T10:35:00","guid":{"rendered":"https:\/\/flcube.com\/?p=22312"},"modified":"2025-01-20T18:38:14","modified_gmt":"2025-01-20T10:38:14","slug":"roche-reports-2-yoy-growth-in-2022-ocrevus-and-hemlibra-drive-sales","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=22312","title":{"rendered":"Roche Reports 2% YOY Growth in 2022; Ocrevus and Hemlibra Drive Sales"},"content":{"rendered":"\n

Swiss pharmaceutical giant Roche (SWX: RO<\/a>) released its 2022 financial report this week, recording CHF 63.3 billion (USD 69.5 billion) in global sales. The company achieved a modest 2% year-on-year (YOY) growth at constant exchange rates (CER), impacted by lower COVID-19-related sales across both its Pharmaceuticals and Diagnostics divisions.<\/p>\n\n\n\n

Pharmaceuticals and Diagnostics Performance<\/strong>
Roche’s Pharmaceuticals unit generated CHF 45.6 billion (USD 50.1 billion) in sales, up 2% YOY. Growth was driven by new treatments for severe diseases, which offset the decline from biosimilar competition and lower sales of the COVID-19 repurposed drug Actemra (tocilizumab). The Diagnostics division expanded by 3% to CHF 17.7 billion (USD 19.5 billion), primarily driven by immunodiagnostic products.<\/p>\n\n\n\n

Top-Selling Pharmaceuticals<\/strong>
The top-selling pharmaceuticals remained consistent with Q3 2022 results. Multiple sclerosis (MS) treatment Ocrevus (ocrelizumab) led with CHF 6.0 billion (USD 6.6 billion) in sales, up 17% YOY. Breast cancer therapy Perjeta (pertuzumab) followed with CHF 4.1 billion (USD 4.5 billion), up 5% YOY. Hemophilia drug Hemlibra (emicizumab) achieved CHF 3.8 billion (USD 4.2 billion) in sales, up 27%. The PD-L1 inhibitor Tecentriq (atezolizumab) recorded CHF 3.7 billion (USD 4.1 billion), up 14% YOY. Meanwhile, four core products facing biosimilar erosion\u2014Actemra, Herceptin (trastuzumab), Avastin (bevacizumab), and MabThera\/Rituxan (rituximab)\u2014saw sales drop by 22%, 19%, 28%, and 21% YOY respectively, resulting in a combined CHF 1.9 billion decline.<\/p>\n\n\n\n

New Launches and Future Outlook
Roche celebrated the global launch of two bispecific antibodies (BsAbs): ophthalmic drug Vabysmo (faricimab) and cancer treatment Lunsumio (mosunetuzumab). The company expects solid underlying growth in both divisions to offset an estimated CHF 5 billion (USD 5.5 billion) decline in COVID-19 product sales, projecting low single-digit growth in 2023.<\/p>\n\n\n\n

China Performance: Mixed Results<\/strong>
Roche’s China performance showed a mixed picture. Pharmaceutical Group sales contracted by 7% YOY to CHF 3.039 billion (USD 3.3 billion) due to biosimilar competition against key products like MabThera\/Rituxan, Herceptin, and Avastin, as well as lower sales of antibiotic Rocephin (ceftriaxone). However, demand for non-small cell lung cancer (NSCLC) drug Alecensa (alectinib), leukemia therapy Gazyva\/Gazyvaro (obinutuzumab), and Perjeta grew. The Diagnostics Division in China expanded by 6% to CHF 2.58 billion (USD 2.82 billion), driven by strong sales of the SARS-CoV-2 Rapid Antigen test and immunoassays business across the Asia-Pacific region.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Swiss pharmaceutical giant Roche (SWX: RO) released its 2022 financial report this week, recording CHF…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[43,16,13,20,27,28,44,18,989],"class_list":["post-22312","post","type-post","status-publish","format-standard","hentry","category-company","tag-biosimilars","tag-cancer","tag-covid-19","tag-finance","tag-finanical-reports","tag-multi-specific-antibodies","tag-ophthalmology","tag-pd-1-l1","tag-swx-ro"],"yoast_head":"\nRoche Reports 2% YOY Growth in 2022; Ocrevus and Hemlibra Drive Sales - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Swiss pharmaceutical giant Roche (SWX: RO) released its 2022 financial report this week, recording CHF 63.3 billion (USD 69.5 billion) in global sales. The company achieved a modest 2% year-on-year (YOY) growth at constant exchange rates (CER), impacted by lower COVID-19-related sales across both its Pharmaceuticals and Diagnostics divisions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=22312\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Roche Reports 2% YOY Growth in 2022; Ocrevus and Hemlibra Drive Sales\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=22312\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-03T10:35:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-20T10:38:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22312#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22312\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Roche Reports 2% YOY Growth in 2022; Ocrevus and Hemlibra Drive Sales\",\"datePublished\":\"2023-02-03T10:35:00+00:00\",\"dateModified\":\"2025-01-20T10:38:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22312\"},\"wordCount\":354,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biosimilars\",\"Cancer\",\"COVID-19\",\"Finance\",\"Finanical Reports\",\"Multi-specific antibodies\",\"Ophthalmology\",\"PD-1\\\/L1\",\"SWX: RO\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22312#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22312\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=22312\",\"name\":\"Roche Reports 2% YOY Growth in 2022; Ocrevus and Hemlibra Drive Sales - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-02-03T10:35:00+00:00\",\"dateModified\":\"2025-01-20T10:38:14+00:00\",\"description\":\"Swiss pharmaceutical giant Roche (SWX: RO) released its 2022 financial report this week, recording CHF 63.3 billion (USD 69.5 billion) in global sales. The company achieved a modest 2% year-on-year (YOY) growth at constant exchange rates (CER), impacted by lower COVID-19-related sales across both its Pharmaceuticals and Diagnostics divisions.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22312#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22312\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22312#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Roche Reports 2% YOY Growth in 2022; Ocrevus and Hemlibra Drive Sales\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Roche Reports 2% YOY Growth in 2022; Ocrevus and Hemlibra Drive Sales - Insight, China's Pharmaceutical Industry","description":"Swiss pharmaceutical giant Roche (SWX: RO) released its 2022 financial report this week, recording CHF 63.3 billion (USD 69.5 billion) in global sales. The company achieved a modest 2% year-on-year (YOY) growth at constant exchange rates (CER), impacted by lower COVID-19-related sales across both its Pharmaceuticals and Diagnostics divisions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=22312","og_locale":"en_US","og_type":"article","og_title":"Roche Reports 2% YOY Growth in 2022; Ocrevus and Hemlibra Drive Sales","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=22312","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-02-03T10:35:00+00:00","article_modified_time":"2025-01-20T10:38:14+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=22312#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=22312"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Roche Reports 2% YOY Growth in 2022; Ocrevus and Hemlibra Drive Sales","datePublished":"2023-02-03T10:35:00+00:00","dateModified":"2025-01-20T10:38:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=22312"},"wordCount":354,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biosimilars","Cancer","COVID-19","Finance","Finanical Reports","Multi-specific antibodies","Ophthalmology","PD-1\/L1","SWX: RO"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=22312#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=22312","url":"https:\/\/flcube.com\/?p=22312","name":"Roche Reports 2% YOY Growth in 2022; Ocrevus and Hemlibra Drive Sales - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-02-03T10:35:00+00:00","dateModified":"2025-01-20T10:38:14+00:00","description":"Swiss pharmaceutical giant Roche (SWX: RO) released its 2022 financial report this week, recording CHF 63.3 billion (USD 69.5 billion) in global sales. The company achieved a modest 2% year-on-year (YOY) growth at constant exchange rates (CER), impacted by lower COVID-19-related sales across both its Pharmaceuticals and Diagnostics divisions.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=22312#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=22312"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=22312#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Roche Reports 2% YOY Growth in 2022; Ocrevus and Hemlibra Drive Sales"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22312","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22312"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22312\/revisions"}],"predecessor-version":[{"id":22313,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22312\/revisions\/22313"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22312"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22312"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}